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Achieving integrated self-directed Cancer
aftercare (ASICA) for melanoma: how a
digital intervention to support total skin
self-examination was used by people
treated for cutaneous melanoma
Felicity Reilly1, Lynda Contstable2, William Brant3, Kaz Rahman4, Amer Durrani5, Nigel Burrows5, Charlotte Proby6,
Julia Allan7, Marie Johnston7, Derek Johnston7, Fiona Walter8 and Peter Murchie1*
Abstract
Background: Melanoma incidence has quadrupled since 1970 and melanoma is now the second most common
cancer in individuals under 50. Targeted immunotherapies for melanoma now potentially enable long-term
remission even in advanced melanoma, but these melanoma survivors require ongoing surveillance, with
implications for NHS resources and significant social and psychological consequences for patients. Total skin self-
examination (TSSE) can detect recurrence earlier and improve clinical outcomes but is underperformed in the UK.
To support survivors, the Achieving Self-directed Integrated Cancer Aftercare (ASICA) intervention was developed to
prompt and improve TSSE performance, with subsequent reporting of concerns and submission of skin photos to a
Dermatology Nurse Practitioner (DNP). ASICA was delivered as a randomized pilot trial.
Methods: This paper reports on process evaluation. Data on participants’ demographics and the concerns they
reported during the trial were tabulated and displayed using Microsoft Excel and SPSS. We explored which
participants used ASICA, and how frequently, to report any skin concerns. We also determined how the interactions
had worked in terms of quality of skin photographs submitted, clinical assessments made by the DNP, and the
assessments and decisions made for each concern. Finally, we explored significant events occurring during the trial.
Data on participants’ demographics and the concerns they reported during the trial were tabulated and displayed
using SPSS. A semi-structured interview was undertaken with the DNP to gain perspective on the range of
concerns presented and how they were resolved.
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Results: Of 121 recruited melanoma patients receiving ASICA for 12 months, 69 participants submitted a total of
123 reports detailing 189 separate skin-related concerns and including 188 skin photographs. Where participants
fully complied with follow-up by the DNP, concerns were usually resolved remotely, but 19 (10.1%) were seen at a
secondary care clinic and 14 (7.4%) referred to their GP. 49 (25.9%) of concerns were not completely resolved due
to partial non-compliance with DNP follow-up.
Conclusion: Melanoma patients randomized to the ASICA intervention were able to report skin-related concerns
that could be resolved remotely through interaction with a DNP. Feasibility issues highlighted by ASICA will support
further development and optimization of this digital tool.
Trial registration: Clinical Trials.gov, NCT03328247. Registered on 1 November 2017
Keywords: Primary care, Melanoma, Cancer, Randomised Controlled Trial, Survivorship, Self-directed care, e-health
Background
Melanoma is the fifth most common cancer in the UK,
with over 16,000 diagnoses annually, and accounts for
1% of all cancer deaths [1, 2]. Although melanoma can
be fatal, it has a high relative survival rate at five years,
over 90% in the UK [2, 3]. However, those treated for
melanoma are at risk of recurrence and the development
of further primary melanomas in up to 8% of those ini-
tially diagnosed [4, 5]. Melanoma follow-up and ongoing
surveillance of those treated for melanoma has an im-
portant role in detecting recurrence and new primaries
at the earliest stage, when prompt treatment may im-
prove outcomes [6]. Traditional structured follow-up,
necessitating regular visits to a hospital specialist is
increasingly costly and burdensome for patients and the
NHS and the overall costs of providing NHS care to
patients with skin cancer, in England only, has been
calculated at £190.5 million in 2020 [2, 7].
As an adjunct to structured follow-up, most inter-
national consensus guidelines on melanoma manage-
ment, including those of the British Association of
Dermatologists and the Scottish Intercollegiate Guide-
line Network, recommend that patients should perform
regular total self-skin examination (TSSE) in the inter-
vals between hospital appointments to aid early detec-
tion [8–12]. This may prove instrumental in improving
clinical outcomes with studies showing 62% of melano-
mas being first identified by patients themselves [13, 14].
Although widely recommended, the rate of skin check-
ing by melanoma survivors is only similar to the general
population [15]. Encouraginly evidence of how TSSE can
be promoted and sustained is growing [16].
Digital technology develops apace and is recognized as
a potential solution to a number of healthcare
challenges, especially in rural areas where easy access to
healthcare is often geographically limited [17–19].
Qualitative interviews with melanoma survivors have
supported the view that, with appropriate training and
design, smartphone-based app (application) technology
is an acceptable way to promote and support TSSE [20].
The Achieving Self-directed Integrated Cancer Aftercare
(ASICA) app was developed to prompt, support, record
and respond to TSSE reports by patients who have com-
pleted primary treatment for melanoma. ASICA was an it-
eratively developed evidenced-based app intervention to
support and improve TSSE adherence and practice, using
tablet-based technology [21]. The app, hosted on Android
tablets used animated instructional videos and monthly
prompts to users to support TSSE. The app’s features in-
cluded an individualised digital skin map and the facility
to send electronic reports of any skin concerns, including
photographs, to a remote Dermatology Nurse Practitioner
(DNP), a specialist nurse with additional training and ex-
perience in clinical dermatology. (Fig. 1). Following devel-
opment and feasibility testing, ASICA has undergone a
feasibility randomised controlled trial (RCT) with a nested
qualitative component to gather data on the experiences
of users and intermediate clinical outcomes (to be re-
ported elsewhere) [22]. The ASICA clinical trial aimed to
improve clinical outcomes of melanoma recurrence and
reduce the burden on patients and health services [22]. If
the trial, completed in April 2020 (to be reported else-
where), shows positive outcomes, the ASICA app may be-
come a useful tool in melanoma aftercare within the NHS,
particularly in rural areas.
Aims
This paper reports on the clinical activity generated by
the ASICA intervention. Firstly, we explored which par-
ticipants had used ASICA. Secondly, we explored the
frequency with which the participants who used ASICA
reported concerns and the number of concerns that they
submitted for consideration by the dermatology nurse
practitioner (DNP). Thirdly, we explored the quality of
skin photographs submitted, the clinical assessments
made by the DNP, and the assessments made for each
concern. Fourthly, we present the data on significant
events occurring during the trial and the outcome of in-
stances when users were referred to their GP or seen
face-to-face in secondary care.
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Methods
The full methodology, including flow chart, is described
in the published protocol [22]. This report focuses on
the clinical activity generated by participants using the
ASCIA intervention as part of a randomized controlled
trial reported elsewhere. The full trial was registered at
Clinical Trials.gov, NCT03328247 on 01/11/2017
(https://clinicaltrials.gov/ct2/show/NCT03328247?term=
ASICA&rank=1).
Adults (over the age of 18) who had completed treat-
ment within the previous 60 months for a stage 0-2C
primary cutaneous melanoma were invited to participate
in the ASICA feasibility RCT. Participants required wire-
less connectivity at home with sufficient capability to
transmit images of skin concerns taken using the
Samsung Galaxy 7″ tablets in-built camera. Patients
were excluded if they had stage 3 or 4 melanoma, had a
recurrence of melanoma within the last 60 months, were
not able to consent to participate or complete question-
naires, or were blind or visually impaired.
ASICA was an open multi-centre two arm feasibility
RCT which recruited 241 participants from two UK
NHS secondary care sites (NHS Grampian and
Cambridge University Hospitals NHS Foundation Trust).
Ethical approval was given by the National Research
Ethics Service (NRES) Grampian Ethics committee on
28th April 2017(Reference Number 17/NS/0040), and all
participants gave written informed consent. No partici-
pant received any remuneration to take part.
Figure 2 is a modified CONSORT diagram showing
the flow of participants into the intervention and control
groups. Participants were randomized to the ASICA
intervention plus standard care, or standard care alone
in a 1:1 ratio, minimized on gender and centre, using a
Fig. 1 Schematic diagram representing the function of the ASICA intervention
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validated remote computer-automated randomization
system hosted at the Centre for Healthcare Randomized
Trials (CHaRT) in Aberdeen, UK. Blinding was not pos-
sible due to the requirement to operate the ASICA app
(or not). This report focusses only on those participants
randomized to the ASICA app, further information on
participants in both groups will be presented elsewhere.
Participants randomised to the ASICA intervention
were invited to attend the local medical photography
suite to have a standard set of full body digital skin pho-
tographs taken. At their attendance it was explained that
the intention was to take a series of digital images of
their whole body to form a digital skin map to which
they would be able to refer during the trial. Patient were
then asked to provide written consent before the medical
photographer took a set of 12 standard body map images
using a digital camera (Fig. 3). These images were then
used to create individual skin-maps which were
uploaded to a secure server and individuals could refer
to their own skin maps via the internet at any time dur-
ing the trial. The ASICA intervention group received a
Samsung Galaxy 7″ tablet preloaded with the ASICA
app and received comprehensive training to use the app
(in person, group and written instructions). The ASICA
app included an instructional video on how to sequen-
tially conduct a TSSE. Individuals could also use their
Samsung Galaxy 7″ tablet to view their own individual
digital skin map at any time. The device also included a
digital camera and the app included a video which
instructed participants how to take photographs of skin
lesions or other concerns that they had. Finally, the app
had a structured electronic TSSE report form which was
used to send a report, including attached photographs,
of each individual TSSE direct to the DNP for assess-
ment and action as appropriate. Since participants all
had experience of receiving melanoma follow-up exam-
ination no specific directions were given or restrictions
made on the nature of skin concerns that they should
report. No restriction was placed on submitting con-
cerns from intimate body areas. The DNP recorded de-
tails of their assessment of the concern, including skin
photographs, and their diagnosis and clinical decision on
Fig. 2 Modified CONSORT diagram showing patient flow in the ASICA study
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an electronic clinical portal which were revised and im-
proved during the study.
The ASICA intervention group received monthly
prompts (phone, email, text or mail) to conduct a TSSE
and to take a photograph of any concerning skin lesions.
The reports (and images) were uploaded to the hosted
secure server, alerting the clinical nurse specialist (DNP)
to review and follow up.
All participants continued with standard care and
attended their usual structured melanoma follow up as
per local guidelines. All participants also completed
questionnaires (postal or web based, depending on pref-
erence) at 3, 6 and 12months after randomization, with
a further postal reminder if no response after 3 weeks. A
clinical review of medical notes of all participants was
also undertaken 12 months after randomization to col-
lect any relevant pathology data. Additionally, a purpos-
ive sample of members of the intervention group were
recruited to participate in telephone interviews with FR
after 12-months. FR also interviewed the study DNP
after 12 months.
When a participant reported a skin concern using the
ASICA app (see Fig. 1), an automated alert was triggered
and sent to the DNP for review. The DNP consulted
with the participants directly by telephone and recorded
their concerns. Data collected included:
 Area of body that concern related to
 The sharpness and focus of the skin photographs
submitted and if further skin photographs were
required
 DNP assessment of concern
 Further action recommended
Participant demographics and data recorded from the
reports of concerns were collated, organized and tabu-
lated using SPSS [23]. .The data were then cross tabu-
lated by demographic group to determine potential
differences and discrepancies across gender, age, study
centre, and the deprivation and rurality categories linked
to individual participants’ home address [24–27].
Results
Who submitted concerns?
In this paper we report data from the intervention group
of the ASICA study focusing on those who notified con-
cerns about their skin to the study DNP during the
study year. Full details of recruitment and retention will
be reported elsewhere along with the main trial results.
To note, however, of 259 white Caucasian individuals of
Scots, English, Irish and Eastern European origin across
both sites who had been screened as eligible to partici-
pate and were invited to take part in the ASICA trial,
240 (92.7%) consented and 19 (7.3%) declined. Table 1
shows key demographics and the site of primary melan-
oma for all 121 members of the intervention group and
separately those 69 members who submitted concerns to
the DNP using the ASICA app during their 12 months
of receiving the ASICA intervention. Compared to the
intervention group overall, those who submitted con-
cerns were younger and more likely to live rurally. Not-
ably, overall six intervention group participants resided
in the most deprived Scottish quintile, and only one of
these six submitted a concern with their skin during the
study year.. Submitters from the Grampian site num-
bered 49 (68%) with 20 (32%) from the Cambridge site.
There were slightly more females than males submitters
Fig. 3 Standard skin-mapping protocol for ASICA digital skin maps
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(55.1% to 44.9) and their mean age was 57.5 years (SD
13.6 years), but participants submitters concerns had a
wide range of ages, both younger and older patients.
Overall 6 (8.7%) submitters resided in the most-deprived
five deciles compared to 15 (22%) coming from the sin-
gle most affluent decile. [Scottish Government 2020; UK
Government 2019] Over half of submitters were rural-
dwellers (n = 38 (55.1%), with a similar proportion living
rurally at each site, 28 (51.9%) from Grampian and 10
(50.0%) from Cambridge.
How often were concerns submitted?
During the 12months follow up, 61 participants re-
ported active concerns about their skin using the ASICA
app on 129 occasions [Median 2; Interquartile range
(IQR) 1–2; Range (1–8)] Concerns were new pigmented
skin lesions, changes to existing pigmented skin lesions,
new or changing lumps associated with the skin, or a
range of miscellaneous concerns including issues with
their original primary melanoma excision scar, skin
rashes, and nail changes (Table 2). The majority of re-
ports comprised one or two concerns (109/129 (84%)),
but on 14 occasions between three and eight separate
concerns were included and detailed in the report
(Table 2). Thus although 129 separate reports were
submitted, they included a total of 190 separate skin
concerns. The number of separate skin concerns
submitted by any one individual throughout the trial
varied from 1 to 16 [Median 2; IQR 1–3].
What was the range and nature of concerns submitted?
Table 3 summarizes the number of reports submitted
and whether they related to the site of the first primary
melanoma or another site. Approximately 62% (117/189)
of reports submitted detailed concerns at sites other
than the primary. Concerns about a new mole or
changes to existing moles accounted for almost 60% of
reports submitted. Further, 20% of concerns detailed
“other concerns” such as skin rashes (2 diagnoses of
shingles), nail changes and other types of non-
pigmented skin lesions. Body location of reported con-
cerns were roughly evenly distributed among head and
neck, upper and lower limbs and torso, with a smaller
number (6/189 (3.2%)) arising in the pelvic area.
How good were the skin photographs that were
submitted?
Almost a quarter (45/188 (23.9%)) of initially submitted
skin photographs were of prime focused quality, with
some blurring reported by the DNP in around two thirds
Table 1 Demographics of individuals who submitted concerns using ASICA (n = 69)
Intervention Group (n%) Submitted a concern (n%) Grampian n(%) Cambridge n(%)
Participants 121 (100) 69 (100) 49 (62) 20 (38)
Gender n(%) n (%) n (%) n (%)
Male 55 (45.5) 31 (44.9) 21 (42.9) 10 (50.0)
Female 66 (54.5) 38 (55.1) 28 (57.1) 10 (50.0)
Age Mean (SD) Mean (SD) Mean (SD)
Whole Sample 59.1 (14.1) 57.5 (13.6) 58.7 (14.1) 54.5 (12.2)
Female 56.8 (13.7) 55.9 (12.5) 55.5 (13.4) 56.7 (10.5)
Male 62.9 (14.2) 59.5 (14.9) 62.8 (14.3) 52.4 (14.2)
Location of Primary Melanoma n(%) n (%) n (%)
Head and Neck 22 (18.2) 11 (15.9) 8 (16.3) 3 (15.0)
Lower Limbs 32 (26.4) 19 (27.5) 13 (26.5) 6 (30.0)
Upper Body 46 (38.0) 25 (36.2) 19 (36.8) 6 (30.0)
Upper Limbs 21 (17.4) 14 20.3)) 9 (18.4)) 5 (25.0)
Deprivation Quintile n (%) n (%) n (%)
1 – Most Deprived 2 (1.7) 0 (0) 0 (0) 0 (0)
2 4 (3.3) 1 (1) 1 (2) 0 (0)
3 21 (17.4) 16 (23.2) 11 (22.5) 5 (25.0)
4 38 (31.4) 25 (36.2) 18 (36.9) 7 (35.0)
5 – Least Deprived 56 (46.3) 27 (39.1) 18 (38.7) 8 (40.0)
Rurality N (%)
Urban 72 (59.5) 32 (46.4) 22 (44.9) 10 (50.0)
Rural 49 (40.5) 37 (53.6) 27 (55.1) 10 (50.0)
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(118/188 (62.7%)) (Table 4). Nevertheless 79 (41.4%)
skin photographs were of sufficient quality to make a
clinical decision. Further skin photographs were re-
quested by the DNP on 111 occasions (58.6%). The pa-
tient returned these on 48 occasions (25.5%) but did not
on 61 (33.5%) occasions. The rate of not returning
further skin photographs appeared higher (53.5% vs
21.2%) in the Cambridge patients.
How were participant concerns resolved?
Of the 189 concerns reported 188 included a skin photo-
graph. 62 (32.8%) concerns were resolved in telephone
Table 2 Frequency and number of concerns* submitted using ASICA
Number of reporting occasions per individual Overall n (%) Grampian n (%) Cambridge n (%)
1 28 (45.9) 19 (46.3) 9 (45)
2 20 (32.8) 14 (34.1) 6 (30)
3 8 (13.1) 4 (9.8) 4 (20)
4 1 (1.6) 1 (2.4) 0 (0)
6 2 (3.3) 2 (4.9) 0 (0)
7 1 (1.6) 0 (0) 1 (5)
8 1 (1.6) 1 (2.4) 0 (0)
Test image only 8 7 1
TOTAL 123 (100) 83 (100) 40 (100)
Number of concerns included per report Overall n (%) Grampian n (%) Cambridge n (%)
1 86 (45.5) 61 (51.2) 26 (36.6)
2 23 (12.1) 17 (14.2) 6 (8.5)
3 7 (3.7) 4 (3.4) 3 (4.2)
4 4 (2.1) 1 (10.8) 3 (4.2)
5 0 (0) 0 (0) 0 (0)
6 2 (1.0) 0 (0) 2 (2.8)
7 0 (0) 0 (0) 0 (0)
8 1 (0.5) 1 (0.8) 0 (0)
TOTAL 189 119 71
Number of concerns reported overall
1 21 (36.1) 13 (31.7) 9 (45.0)
2 19 (31.1) 15 (36.6) 4 (20.0)
3 6 (9.8) 6 (14.6) 0 (0)
4 4 (6.6) 2 (4.9) 2 (10.0)
5 2 (3.3) 1 (2.4) 1 (5.0)
6 2 (3.3) 0 (0.0) 2 (10.0)
7 0 (0) 0 (0) 0 (0)
8 1 (1.6) 1 (2.4) 0 (0)
9 1 (1.6) 1 (2.4) 0 (0)
10 0 (0) 0 (0) 0 (0)
11 2 (3.3) 1 (2.4) 1 (5.0)
12 0 (0) 0 (0) 0 (0)
13 0 (0) 0 (0) 0 (0)
14 0 (0) 0 (0) 0 (0)
15 1 (1.6) 0 (0) 1 (5.0)
16 1 (1.6) 1 (2.4) 1 (0)
TOTAL 189 119 71
*Concerns were new pigmented skin lesions, changes to existing pigmented skin lesions, new or changing lumps associated with the skin, or a range of
miscellaneous concerns including issues with their original primary melanoma excision scar, skin rashes, and nail changes (see also Table 5)
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conversation between the participant and the DNP and
based on the initial skin photographs sent. On 28 occa-
sions (14.8%) the concern was resolved when the partici-
pant and the DNP spoke initially and then again after
the participant had submitted further skin photographs
for assessment by the DNP. Face-to-face consultations
were triggered on 33 (17.5%) occasions:: on 14 (7.4%) oc-
casions participants were referred to their GP and for 19
(10.1%) participants an appointment was arranged at a
face-to-face dermatology clinic. In around one third (66/
189) of reports, the participants who reported a concern
did not respond to a subsequent request for further im-
ages, with the DNP having made an assessment that the
issue was initially benign for 17 of these. However, in
total, this means that 49 concerns were not resolved by
the DNP within the trial. It is important to be quite
clear, however, that this had been anticipated in design
and that the ASICA intervention was being delivered to
participants in addition to their usual follow-up and pri-
mary and secondary care.
The range of assessments made by the DNP on par-
ticipant reports of concern are shown in Table 5. The 61
“Benign (non-specific)” assessments were occasions
where the DNP had felt that the patient could be reas-
sured on the basis of his review of the clinical history
and skin photographs submitted and did not require
more detailed assessment or treatment. That there are a
relatively large number of concern outcomes classified in
this way, i.e. not attached to a specific diagnosis results
from the fact that the trial clinician portal for receiving
and detailing the assessment of submitted reports was
improved about midway through the study enabling
more clinical detail to be collected.
It was observed that individuals varied considerably in
the interval between training and the first report of a
concern being submitted. The first report was received
within one month from 29 (42.0%) participants. The first
report was received between one and three months by
20 (29.0%) participants, between three and six months
from 11 (15.9%) participants and between six and 12
months from a further 9 (13.0%) participants. This dem-
onstrates that the timing of individuals submitting their
first report was spread throughout the study period and
not clustered around training dates.
What significant clinical events occurred?
These data are included to demonstrate practical appli-
cations of the intervention in a real-world setting.
Table 6 details significant clinical events (diagnoses of
metastatic melanoma, new primary melanoma and dys-
plastic naevi) and episodes where an ASICA report led
to the DNP referring a patient to their GP or arranging
for them to be seen face-to-face by a skin specialist in a
secondary care clinic. As a result of using ASICA, 14
participants were referred to their GP and 19 face-to-
face assessments were arranged at a dermatology out-
patient clinic. We are not able to report on the detailed
outcome of all these primary and secondary care en-
counters since we did not have sufficient access to pri-
mary and secondary care case-notes to triangulate these
completely. Furthermore, due to the timescales involved
not all episodes were concluded within the trial follow
Table 3 Nature of concerns indicated by reporting participant
Overall Grampian Cambridge
n (%) n (%) n (%)
Number of reports submitted 189 (100) 118 (100) 71 (100)
Number of concerns raised relating to original primary site 61 (31) 39 (33.1) 22 (31.0)
Number of concerns relating to other site 128 (69) 79 (66.9) 49 (69.0)
Not clear
Participant designation of concern
New mole 54 (28.6) 28 (23.7) 26 (36.6)
Change in existing mole 57 (30.2) 32 (27.1) 25 (32.2)
Lump on skin 28 (14.8) 24 (20.3) 4 (5.6)
Lump under skin 11 (5.8) 6 (5.1) 5 (7.0)
Other 39 (20.6) 28 (23.7) 11 (15.5)
Location of concern reported n (%) n (%) n (%)
Head and Neck 33 (22.8) 25 (21.2) 18 (25.4)
Upper Limbs 43 (17.5) 23 (19.5) 10 (14.1)
Lower Limbs 47 (24.9) 27 (22.9) 20 (28.2)
Torso 60 (31.7) 37 (31.4) 23 (32.4)
Pelvic Region 6 (3.2) 6 (5.1) 0 (0)
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up period, with some appointments, results and proce-
dures outstanding. We also collected data on diagnoses of
recurrent melanoma and metastatic melanoma, new pri-
mary melanoma and new dysplastic lesions in the 12-
month clinic reviews, since these are potential outcomes
in a definitive trial of ASICA. Whilst we were able to col-
lect this data, these events were rare with only two ASICA
participants being diagnosed with metastatic melanoma,
one with a new primary melanoma and one with two dys-
plastic naevi. These four events are detailed in Table 6 al-
though, all occurred in the period between randomization
and patients being trained and receiving the intervention.
Thus, ASICA was not directly involved in any of these
diagnoses. Table 6 also includes details of 5 of the 19 cases
where patients were brought to a secondary care clinic for
face to face assessment, where and details of the clinical
outcome was available when outcome data were collected
from participants’ medical records. In the further 14 cases
details of the final clinical outcome were still awaited at
the time outcome data were collected.
Practical experiences of users and the dermatology nurse
practitioner?
Telephone interviews were conducted 13 members of
the intervention group. Of these eight were male, five
were female and the age range was 39–86. Eight lived in
a rural setting and five in an urban setting. Four were
from the Cambridge site and nine from Grampian. The
interviews demonstrated a range of experiences, behav-
iours, beliefs and feelings with respect to their skin, skin
checking and technology. Most participants stated that
they had already checked their skin regularly, but that
using ASICA increased frequency/consistency of check-
ing and supported a more systematic approach to skin-
checking. Some users also reported that ASICA had im-
proved their confidence about when and how to check
their skin. ASICA users were almost universally well-
disposed to technology becoming integral part of their
health care, with the caveat that personal interaction
DNP had helped make the intervention work. Most saw
the potential of digital technology and the likelihood that
it will be increasingly used to facilitate healthcare in the
future. Participants and the study DNP made several
suggestions to improve usability and functionality. The
hardware provided, was criticised, with several partici-
pants reporting issues with the camera and operating
system. The hardware (i.e. the tablet) was reported as
the main barrier to the ASICA app’s use. Most partici-
pants did not believe ASICA had changed their feelings
around skin checking, but it had raisied awareness and
Table 4 Quality of submitted images, further images and clinical decisions
Quality of initial submitted images Overall Grampian Cambridge
n (%) n (%) n (%)
Focused 45 (23.9) 34 (28.8) 11 (15.5)
Blurred 118 (62.7) 67 (56.8) 51 (71.8)
Not Stated 25 (13.2) 16 (13.6) 9 (12.7)
No Image Submitted 1 (0.5) 1 (0.8) 0 (0)
189 118 71
Request for further images
None requested 79 (41.4) 61 (50.8) 18 (25.4)
Requested and received 48 (25.5) 33 (28.0) 15 (21.1)
Requested and not received 61 (33.5) 23 (21.2) 38 (53.5)
Resolution of concern n (%) n (%) n (%)
Resolved by assessment of ASICA images 90 (47.8) 60 (51.3) 30 (42.3)
Required further face-to-face assessment 33 (17.5) 27 (23.1) 6 (8.5)
Partial non-compliance by patient 65 (34.6) 30 (25.6) 35 (49.3)
Resolved with initial images 62 (33.0) 42 (35.9) 20 (28.2)
Resolved after further images sent 28 (14.9) 18 (15.3) 10 (14.1)
Seen at a secondary care clinic 19 (10.1) 15 (12.8) 4 (5.6)
Referred to GP 14 (7.4) 10 (8.5) 4 (5.6)
Benign but confirmatory further images not sent by patient 17 (9.0) 2 (1.7) 15 (21.1)
Not completed due to patient not sending further images 48 (25.5) 29 (24.8) 20 (28.2)
188 117 71
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changed their own skin checking behaviours for the bet-
ter. Overall, using ASICA did not appear to increase
anxiety in the long-term. Some participants suggested
that ASICA temporarily and briefly increased anxiety
about skin-checking at the start, but that this has settled
over time with regular use. In contrast, several partici-
pants viewed the app as a means of accessing rapid re-
assurance when concerns arose.
Discussion
Summary of main findings
This feasibility RCT has demonstrated that over half of
the participants previously treated for melanoma ran-
domized to the intervention group (57%) were able to
use the ASICA intervention can enable to report con-
cerns with their skin. Most of these (74.5%) then inter-
acted with a remote specialist DNP to resolve these
concerns. The participants who used ASICA were demo-
graphically diverse. Further, it appeared that those
reporting concerns, compared to the intervention group
overall, were slightly younger, more likely to live rurally
and less likely to be socioeconomically deprived. There
was also a greater tendency for those at the Cambridge
site to not send a further skin photograph when re-
quested by the DNP. Participants use of ASICA to re-
port skin concerns appeared to be sustained throughout
the 12-month study period as opposed to concentrated
around training with subsequent decline, with a wide-
range of different skin concerns reported. The effective-
ness of the intervention appeared to be constrained by
the quality of the images achieved with the device and
also by participants frequently defaulting from sending
further images. A small number of significant events oc-
curred in the intervention group, but their detection was
did not result from ASICA use. On the other-hand the
trial demonstrated the facility of the ASICA intervention
to recognize significant concerns which could be re-
ferred to participants’ GPs or hospital out-patient de-
partments for subsequent resolution.
Context with other literature
Experience of using digital healthcare generally, and for
melanoma follow-up in particular, is growing but good
quality evidence from rigorous real-world trials is re-
quired to move interventions from the innovation and
introductory phase to become an effective means of
healthcare delivery [28]. In that context the data
presented here provide useful evidence of the scope and
potential of a sequentially developed intervention to ef-
fectively support remote follow-up for those treated for
melanoma. The data presented here are useful in provid-
ing reassurance that the common concerns of those in
melanoma follow-up can be appropriately identified
using remote technology. This accords with the findings




Angioma/Seborrhoeic Keratosis 1 (0.5)
Benign - Excoriated Papule 1 (0.5)
Benign - Insect Bite 1 (0.5)
Benign - Melanocytic Naevus 1 (0.5)
Benign - Trauma 1 (0.5)
Benign (non-specific) 61 (32.3)
Benign Naevus 6 (3.2)
Benign Naevus/Giant Comedone 2 (1.1)
Benign Naevus/Seborrhoeic Wart 1 (0.5)
Benign Nail Change 1 (0.5)
Benign Papilloma 1 (0.5)
Benign Papule (resolved) 1 (0.5)
Benign wart 3 (1.6)
Blister 1 (0.5)
Campbell De Morgan spot 1 (0.5)
Change in WLE scar (proved benign) 1 (0.5)
Concerning (Clinical Input Needed) 1 (0.5)
Concerning (non-specific) 1 (0.5)
Concerning Naevus 2 (1.1)
Concerning Naevus Between Toes 1 (0.5)
Dermal Naevus 2 (1.1)
Dermatitis 2 (1.1)
Dermatofibroma 1 (0.5)
Dry skin 5 (2.6)
Dry Skin (Chronic Venous Insufficiency) 2 (1.1)
Fungal Nail Infection (Not Relevant) 1 (0.5)
Local Inflammation 1 (0.5)
Meibomian Cyst 1 (0.5)
Nail Pigmentation 1 (0.5)
Nail Pigmentation (Traumatic) 1 (0.5)
None Formed 49 (25.9)
None Formed (had biopsy at clinic) 1 (0.5)
None Formed (resolved) 2 (1.1)
Not Relevant to Study 2 (1.1)
Paryonychia 1 (0.5)
Ruptured Hair Follicle 1 (0.5)
Seborrhoeic Keratosis 19 (10.1)
Shingles 2 (1.1)
WLE Scar 1 (0.5)
WLE Scar (healing) 1 (0.5)
WLE Scar foreign body, infection, recurrence 1 (0.5)
Total 189 (100)
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Clinical abstract Definitive outcome if available
1 NA Significant event Randomized but metastases diagnosed subsequently.
Underwent training but subsequently deceased.
Metastatic melanoma – deceased
2 3 Referred to GP Submitted images of three naevi with benign
appearance. Advised to see GP for further follow-up.
No GP referrals made
3 2 Clinic Submitted images of two lesions on back. Underwent
excision of these.
Not available
4 NA Significant event Diagnosed with dysplastic naevi between
randomization and training. Underwent training on,
used app during trial
New dysplastic naevus
5 1 Clinic Submitted images of pigmented lesion near primary
scar on right foot on. Subsequently underwent punch
biopsy at Dermatology OPD on and attended for
dressings. Benign compound naevus diagnosed
Benign naevus
6 1 Clinic Sent images of itchy and raised areas on primary scar
on right foot. Was seen by Consultant and DNP at
clinic with no abnormality detected.
Not available
7 2 Clinic Submitted images of two lesion on vertex of scalp. Had
punch biopsies performed at plastic surgery.
Not available
8 1 Clinic Submitted images of a pink lump around initial primary
scar site. Was seen at clinic by Consultant and DNP
including dermoscopy with no further concerns
indicated.
Benign skin change
9 1 Clinic Submitted image of lesion on right thigh. Seen at
Plastic Surgery OPD for punch biopsy. Pathology
reported benign dermatofibroma
Benign dermatofibroma
10 1 Clinic Submitted images of new growth on primary scar on
left thigh. Was seen at Dermatology OPD and found to
have stitch within scar.
Foreign body in primary scar
11 2 Clinic Submitted images of two lesion on back. Seen in
Plastic Surgery OPD for excision biopsy of both.
Not available
12 2 Referred to GP Submitted images on lesion of left arm on and
discoloration under nail of left index finger. From initial
and further images and history impression was of
trauma to finger and benign papilloma. Referred to GP
for further assessment if changing.
Benign papilloma and subungual
haematoma
13 NA Significant event At time of randomization had pathology outstanding
which proved to be a second primary. The participant
was trained and continued in the trial.
Second primary melanoma diagnosed
between recruitment and training.
Participant continued to engage with trial.
14 1 Clinic Submitted image of lesion on right eyebrow. Seen by
DNP at Dermatology OPD diagnosed with seborrheic
keratosis
Seborrheic keratosis
15 NA Significant event Randomized and trained – primary site on torso. Skin
biopsy before randomization proved to be a metastatic
deposit on left shin. Participant continued in the trial.
Submitted images of new skin rash and seen in
Dermatology OPD. Diagnosis was drug induced rash
secondary to Pembrolizumub.
Metastatic melanoma
16 1 Clinic Submitted image of possible changes in existing mole
on right leg. Seen at Dermatology clinic (date not
available) diagnosis was benign, no procedure
recorded.
Not available
17 1 Referred to GP Submitted image of new naevus on right lower
abdomen. Had been seen by earlier by Plastic Surgeon
not concerned. DNP made benign assessment based
on images asking patient to consult with GP if further
changes.
Not available
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of literature review which reviewed 114 papers (includ-
ing 14 systematic reviews) capturing 20 years of tele-
dermatology research and concluding that it is an
efficient and effective healthcare service compared to in-
person care [29]. The reviewers further concluded that
tele-dermatology reduces patients’ travel time and
waiting time, avoids (unnecessary) dermatologic visits,
and improves access of care to underserved patients.
Our data echoes this to some extent, since over half of
our participants using the intervention successfully were
rural residents, and they also appeared slightly more
likely to do so than the urban recruits [29].







Clinical abstract Definitive outcome if available
18 1 Clinic Submitted image of warty lesion on left ankle. Was
seen in Plastics OPD and excision biopsy on.
Subsequent pathology revealed a seborrheic wart.
Seborrheic wart
19 1 Clinic Submitted image of lesion on left cheek/pre-auricular
area. Was seen in Dermatology clinic by DNP. Lesion
subsequently excised by Plastic Surgeon with
subsequently pathology reporting a basal cell
carcinoma
Basal cell carcinoma
20 1 Referred to GP Submitted images of “erythematous papule with some
telangectasia” on left upper back. Asked to consult GP
for further assessment. GP referred patient to
Dermatology and was seen first and then again for
punch biopsy. Pathology reported a ruptured hair
follicle.
Ruptured hair follicle
21 3 Referred to GP Participant submitted blurred images of three
potentially new lesions. DNP called and elicited no
worrying features in history. Invited new images or
suggested GP review as easier for older rural patient.
Patient saw GP, no worrying features and no further
referral deemed necessary.
Not available
22 2 Referred to GP Participant submitted images of two warty lesion on
left forearm. Further images requested by DNP
revealing no worrying features in history or
appearance. Participant asked to consult GP if changes
with no subsequent GP referral.
Not available
23 1 Clinic Submitted image of lesion on mid-back. Referred to
Dermatology clinic and seen. Subsequent pathology re-
ported as “Dysplastic naevus.”
Dysplastic naevus
24 1 Clinic Submitted image of lesion on right upper abdomen
“existing mole become scaly.” Referred to Dermatology
clinic and seen. Details of outcome not available.
25 1 Referred to GP Submitted images of lump in lower mid-lumbar area.
Contacted by DNP and advised to see GP for assess-
ment. DNP contacted in one week GP had diagnosed
“lipoma” and referred to Dermatology outpatient clinic.
See there with subsequent diagnosis of “spindle cell
lipoma.” Not clear if biopsy was performed.
Spindle cell lipoma
26 1 Clinic Patient submitted image of new red area around scar
site feeling slight raised and blanching with pressure.
Was referred to Dermatology clinic and had
appointment within two weeks. No further details of
outcome available.
Not available
27 1 Referred to GP Submitted images of new lesion on anterior right
thigh. Following further images and phone call with
DNP decided lesion was benign. But participant
advised to monitor and report changes to GP. No
subsequent GP referrals noted.
Not available
28 1 Clinic Submitted image of discolouration in nailbed of right
thumb under nail. Referred to Dermatology clinic and
seen by consultant. Given reassurance and no further
action required.
Not available
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On the other hand, those from a deprived background
were under-represented in our study, as in many other
studies of digital healthcare, which represents a chal-
lenge for future researchers. Further, of six recruits from
the two most deprived quintiles, only one reported a
concern using ASICA in the year. This accords with a
further review of using smartphones and instant messa-
ging which found evidence of their potential to support
remote dermatology in the developing world, so it seems
self-evident that there is a need for research to under-
stand how socioeconomically disadvantaged populations
in the developed world can benefit most [30]. On the
other hand the fact that six individuals from the UKs
most deprived quintiles have participated in this trial,
and at least one individual used the intervention success-
fully is encouraging, but suggest that much more must
be done to engage those of lower socioeconomic status
in developing digital healthcare. A further world-wide
review emphasized the growing scope and potential of
tele-dermatology to deliver many different aspects of re-
mote dermatology care [31]. The review concluded that
teledermatology increases patient satisfaction, reduces
wait times and decrease costs. Underserved communities
and those in rural settings are also more likely to have a
dermatologic evaluation by a specialist via teledermatol-
ogy [31]. Our data certainly provide objective evidence
to support these points. One caveat, however, is our
finding that those at the Cambridge site were consider-
ably less likely to submit second skin photographs when
requested by the DNP, compared to those individuals in
the same health board area as him. This could be be-
cause that individual was more relatable to individuals in
the same area, which has implications for future
upscaling of digital healthcare delivery. Finally, our data
provide important information about how participants
have interacted with a digital healthcare intervention,
which strongly supports a view of digital interventions as
a means for “testing and advancing theories of behaviour
change by generating ecologically valid, real-time object-
ive data.” [32] This point will be developed in a further
paper reporting on adherence in the ASICA trial.
Strengths and limitations
ASICA was a relatively large two-centred feasibility trial
of a novel digital intervention to prompt, record and re-
spond remotely to total-skin-self-examination by those
previously treated for melanoma. Consequently, this ap-
proach confers the advantage that the approach and re-
sults reported here were rigorously produced. We have
demonstrated that patients treated for melanoma are
willing to be recruited to a trial of remote and self-
directed follow-up and that it appears attractive to
people across the demographic range of those diagnosed
with melanoma. We have also demonstrated that the
target group were willing to be randomized, which is
useful information for a subsequent definitive evaluation.
The current report further demonstrates that ASICA is
sufficiently technologically robust to enable a remote
DNP in Northeast Scotland to complete rapid and ap-
propriate assessment of concerns submitted by partici-
pants at sites in both Scotland and England. Further we
have learned much about how the intervention interface
needs to be improved and reprogrammed for subsequent
development, evaluation and eventual implementation.
We have also gained much knowledge about trial pro-
cesses for further definitive evaluation.
We acknowledge several limitations. With advances in
technology, some aspects of the ASICA intervention
proved unwieldy in the pilot trial. As the presented data
demonstrate, the initial images submitted by patients
were frequently of insufficient quality for the DNP to
make a reasonable initial assessment. This resulted in
participants needing to be contacted to submit further
images, introducing delay which was antithetical to the
purpose of the intervention. This led to the most striking
limitation of the study which was that a considerable
number of participants did not submit further photo-
graphs when requested, meaning that the initial concern
raised could not be completely resolved. Unfortunately,
we do not have the data to explain this sufficiently.
However, we would speculate that, since most of the
concerns submitted during the trial were benign in na-
ture, on the occasions when participants defaulted on
submitting further photographs may be because their
level of concern was not high enough to motivate the
further effort of taking and submitting further images. It
should also be pointed out that all the participants were
still in receipt of regular structured hospital follow-up
and may have been sufficiently close to their next ap-
pointment to await that when a technical challenge
arose. We believe, however, that once the technical
specification of ASICA can be improved this issue will
be mitigated. A further potential limitation is under-
reporting of issues on hard-to-see areas of the body and
it is notable, for example, how few concerns from the
pelvic region were submitted. An additional limitation to
the further development of ASCIA is that the DNP re-
ceiving and acting on the reports is a highly skilled and
experienced DNP comfortable with remotely assessing
concerns submitted by this high-risk group. If ASICA is
to be used at scale in future, appropriately skilled indi-
viduals will need to be identified or training will need to
be developed for less experienced individuals. We were
reassured that most of the concerns submitted during
the present trial were non-concerning, with only a rela-
tively small number triggering GP or hospital appoint-
ments. Consequently, we believe it will be possible to
train less-specialized nurses to undertake initial triage of
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submitted lesions and to recognize many of the concerns
submitted. It should also be noted that the trial was con-
ducted over 12 months only and subsequent evaluation
should explore whether use of ASICA to support TSSE
can become sustained in the medium to longer-term. It
must also be acknowledged that a considerable propor-
tion of intervention group participants did not use
ASICA and, at the time of writing, a detailed analysis of
ASICA adoption and adherence is being completed and
will subsequently be submitted for publication.
Additionally, a proportion of users and non-users took
part in qualitative interviews about their experiences.
We have reported data from the ASICA users here but a
fuller report which will also be published separately.
Conclusion and implications
The ASICA feasibility RCT has demonstrated that most
skin concerns submitted by melanoma survivors, and
ranging from minor skin rashes to new moles, can be
assessed remotely. ASICA can also facilitate prompt re-
ferral to GPs and secondary care clinics for concerning
cases where appropriate.. Overall, there is good evidence
that, with appropriate future development, ASICA has
the potential to transform melanoma survivorship care.
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